Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer

Anticancer Research

Volumn 27, Issue 1 A, 2007, Pages 449-458

  Akaike, Hidenori ^a   Kono, Koji ^a   Sugai, Hidemitsu ^a   Takahashi, Akihiro ^a   Mimura, Kousaku ^a   Kawaguchi, Yoshihiko ^a   Fujii, Hideki ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Gastric cancer; HMGB 1; Macrophage

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER STAGING; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; FEMALE; HMGB1 PROTEIN; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 33847656295     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kelly JL, O'Sullivan C, O'Riordain M, O'Riordain D, Lyons A, Doherty J, Mannick JA and Rodrick ML: Is circulating endotoxin the trigger for the systemic inflammatory response syndrome seen after injury? Ann Surg 225: 530-541, 1997.
2. Schlag G, Redl H and Hallstrom S: The cell in shock: the origin of multiple organ failure. Resuscitation 21: 137-180, 1991.
3. Hartmann G, Weiner GJ and Krieg AM: CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 96: 9305-9310, 1990.
4. Collins LV, Hajizadeh S, Holme E, Jonsson IM and Tarkowski A: Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. J Leukoc Biol 75: 995-1000, 2004.
5. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC and Calderwood SK: HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 6: 435-442, 2000.
6. Erlandsson Harris H and Andersson U: Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 34: 1503-1512, 2004.
7. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH and Suffredini AF: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101: 2652-2660, 2003.
8. Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.
9. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U and Tracey KJ: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101: 296-301, 2004.
10. Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, Tracey KJ and Chiorazzi N: High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 173: 307-313, 2004.
11. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H and Tracey KJ: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192: 565-570, 2000.
12. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ and Odunsi K: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102: 18538-18543, 2005.
13. Strater J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T and Moller P: Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 54: 661-665, 2005.
14. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H and Yasui W: Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196: 163-170, 2002.
15. Kono K, Takahashi A, Ichihara F, Amemiya H, lizuka H, Fujii H, Sekikawa T and Matsumoto Y: Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 8: 1767-1771, 2002.
16. Sutter AP and Fechner H: Gene therapy for gastric cancer: Is it promising? World J Gastroenterol 12: 380-387, 2006.
17. Fukuda K, Tsujitani S, Maeta Y, Yamaguchi K, Ikeguchi M and Kaibara N: The expression of RCAS1 and tumor infiltrating lymphocytes in patients with T3 gastric carcinoma. Gastric Cancer 5: 220-227, 2002.
18. Setala LP, Kosma VM, Marin S, Lipponen PK, Eskelinen MJ, Syrjanen KJ and Alhava EM: Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. Br J Cancer 74: 766-772, 1996.
19. Kuniyasu H, Sasaki T, Sasahira T, Ohmori H and Takahashi T: Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology 71: 129-136, 2004.
20. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM and Schmidt AM: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360, 2000.
21. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A and Abraham E: Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370-7377, 2004.